← Back to Clinical Trials
Recruiting NCT07251114

NCT07251114 AI-assisted Endoscopic Ultrasound Grading of Early Esophageal Cancer Invasion Depth: A Multicenter, Prospective, Randomized Cohort Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07251114
Status Recruiting
Phase
Sponsor Fujian Provincial Hospital
Condition Esophageal Cancer Stage
Study Type INTERVENTIONAL
Enrollment 200 participants
Start Date 2025-11-20
Primary Completion 2027-10-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Artificial Intelligence system

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 200 participants in total. It began in 2025-11-20 with a primary completion date of 2027-10-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study mainly uses an artificial intelligence system to assist in the classification of the depth of invasion of early esophageal squamous cell carcinoma under ultrasound endoscopy, providing a basis for preoperative T staging and diagnosis and treatment decisions.

Eligibility Criteria

Inclusion Criteria: * Satisfy ①⑧⑨ and one of the following conditions simultaneously: ②③④⑤⑥⑦ ① Age over 18 years old, ② Esophageal ulcer, ③ low-grade intraepithelial neoplasia, ④ high-grade intraepithelial neoplasia, ⑤ patients with esophageal squamous cell carcinoma, ⑥ white patches of esophageal mucosa, ⑦ esophageal polyps, ⑧ with endoscopic examination records and detailed pathological records, ⑨ agree to participate in the study; Exclusion Criteria: * ① Patients who have undergone esophageal cancer surgery, ② those with a history of radiotherapy and chemotherapy for esophageal cancer, ③ patients with missing data.

Contact & Investigator

Central Contact

Wei Liang, MD

✉ fjsllw@163.com

📞 +86 -18120888996

Principal Investigator

Wei Liang, MD

PRINCIPAL INVESTIGATOR

Fujian Provincial Hospital

Frequently Asked Questions

Who can join the NCT07251114 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Esophageal Cancer Stage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07251114 currently recruiting?

Yes, NCT07251114 is actively recruiting participants. Contact the research team at fjsllw@163.com for enrollment information.

Where is the NCT07251114 trial being conducted?

This trial is being conducted at Fuzhou, China, Putian, China, Putian, China, Putian, China and 1 additional location.

Who is sponsoring the NCT07251114 clinical trial?

NCT07251114 is sponsored by Fujian Provincial Hospital. The principal investigator is Wei Liang, MD at Fujian Provincial Hospital. The trial plans to enroll 200 participants.

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology